A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer

Chemoimmunotherapy with anti-programmed cell death 1/ligand 1 and cytotoxic chemotherapy is a promising therapeutic modality for women with triple-negative breast cancer, but questions remain regarding optimal chemotherapy backbone and biomarkers for patient selection. We report final outcomes from...

Descripción completa

Detalles Bibliográficos
Autores principales: Page, David B., Pucilowska, Joanna, Chun, Brie, Kim, Isaac, Sanchez, Katherine, Moxon, Nicole, Mellinger, Staci, Wu, Yaping, Koguchi, Yoshinobu, Conrad, Valerie, Redmond, William L., Martel, Maritza, Sun, Zhaoyu, Campbell, Mary B., Conlin, Alison, Acheson, Anupama, Basho, Reva, McAndrew, Philomena, El-Masry, Mary, Park, Dorothy, Bennetts, Laura, Seitz, Robert S., Nielsen, Tyler J., McGregor, Kimberly, Rajamanickam, Venkatesh, Bernard, Brady, Urba, Walter J., McArthur, Heather L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284878/
https://www.ncbi.nlm.nih.gov/pubmed/37344474
http://dx.doi.org/10.1038/s41523-023-00541-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284878/
https://www.ncbi.nlm.nih.gov/pubmed/37344474
http://dx.doi.org/10.1038/s41523-023-00541-2

Ejemplares similares